ZTS · Zoetis Inc.
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-07-22 | Zoetis Launches Portela® (relfovetmab) in Canada and the European Union |
| 2026-07-15 | Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union |
| 2026-07-14 | Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities |
| 2026-07-07 | Zoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-ND |
| 2026-06-25 | Zoetis to Host Webcast and Conference Call on Second Quarter 2026 Financial Results |
| 2026-06-04 | Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future |
| 2026-06-04 | Zoetis Shares Resources and Tips for New World Screwworm Response and Management |
| 2026-05-21 | Zoetis to Participate in Upcoming Investor Conferences |
| 2026-05-20 | Zoetis Declares Third Quarter 2026 Dividend |
| 2026-05-07 | Zoetis Announces First Quarter 2026 Results |
| 2026-04-02 | Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results |
| 2026-03-12 | Zoetis to Participate in the KeyBanc Capital Markets Healthcare Forum |
| 2026-03-05 | Zoetis to Participate in Upcoming Investor Conferences |
| 2026-03-02 | Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation |
| 2026-02-24 | Zoetis to Participate in the Bank of America Securities 2026 Animal Health Summit |
| 2026-02-12 |
Zoetis Reports Fourth Quarter and Full Year 2025 Results
Reports Revenue of $2.4 Billion, Growing 3%, and Net Income of $603 Million, or $1.37 per Diluted Share, Increasing 4% and 6%, Respectively, on a Reported Basis for Fourth Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 4% Organic Operational Growth in Adjusted Net Income for Fourth Quarter 2025 Reports Adjusted Net Income of $648 Million, or Adjusted Diluted EPS of $1.48, for Fourth Quarter 2025 Reports Revenue of $9.5 Billion, Growing 2%, and Net Income of $2.7 Billion, or $6.02 per Diluted Share, Increasing 8% and 10%, Respectively, on a Reported Basis for Full Year 2025 Delivers 6% Organic Operational Growth in Revenue and 7% Organic Operational Growth in Adjusted Net Income for Full Year 2025 Reports Adjusted Net Income of $2.8 Billion, or Adjusted Diluted EPS of $6.41 for Full Year 2025 Provides Full Year 2026 Revenue Guidance of $9.825 - $10.025 Billion, with Diluted EPS of $6.65 to $6.75 on a Reported Basis, or $7.00 to $7.10 on an Adjusted Basis Expects to |
| 2026-02-05 |
Zoetis Declares Second Quarter 2026 Dividend
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company’s common stock as of the close of business on Monday, April 20, 2026. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES |